Patients with rheumatoid arthritis who failed to respond to prior treatment with biological agents with three different mechanisms of action may respond to treatment with Acthar Gel, according to data from the European League Against Rheumatism Annual European Congress of Rheumatology.
Researchers presented data from six patients with rheumatoid arthritis (RA) enrolled in an ongoing, 17-week study. The patients were between 54 years and 80 years of age with disease duration of between 9 years and 39 years. Eligible patients did not respond to a biologic at the time of enrollment and had failed to respond or insufficiently responded to at least two other biologic drugs with different response pathways.
Patients were assessed during screening and at baseline before being administered a subcutaneous 80 U dose of Acthar Gel (repository corticotropin, Mallinckrodt) every 72 hours for 12 weeks. The patients were then evaluated at week 2, 6, 12, 14 and 16.
Of the six patients who have completed the trial, all had reductions in tender and swollen joint counts from baseline at week 12. Three showed improvement in the Health Assessment Questionnaire (HAQ) score, and the remaining three patients showed no change in HAQ. Improvements in Disease Activity Score in 28 Joints (DAS28) were seen in all six patients, and erythrocyte sedimentation rate and C-reactive protein were improved in four patients. Five of six patients had an improved patient global VAS, and six had improvements in physician global VAS. Improvements were observed in most domains after 4 weeks, according to the researchers.
One patient experienced a mild injection site reaction and one had hypoglycemic episodes. One patient was hospitalized for hip pain unrelated to the injections. No patients withdrew from the treatment due to adverse events, and all events resolved. – by Shirley Pulaws
Don't know if this is an old article or not. It was dated July 1st 2015
In a regulatory filing, Retrophin (RTRX -2.5%) discloses that it settled its lawsuit with Questcor Pharmaceuticals. Under the terms of the settlement, Questcor paid Retrophin $15.5M in exchange for a mutual release of all claims against each other.
Retrophin filed the suit on January 7, 2014, accusing Questcor of violating antitrust laws by monopolizing certain therapeutic drug markets. The spat pertained to a synthetic fragment of Acthar Gel called Synacthen that was owned by Novartis. Retrophin offered Novatis $16M for the product with the intent of competing against Acthar. On the day Retrophin was to sign the deal, Questcor offered Novartis $135M, which Novartis accepted, considering that it could keep the money even if Questcor lost its rights to the product on antitrust grounds. Retrophin claimed that Questcor's intent was just to eliminate a competitive threat.
Orexigen Therapeutics (NASDAQ:OREX) enters into a supply agreement with Mallinckrodt (NYSE:MNK) for naltrexone, one of the active ingredients in its obesity pill Contrave. Orexigen will buy naltrexone at fixed prices, subject to certain limitations. The agreement will be effective through December 2018.
The only one I see so far today is from Jefferies who raises PT from 140.00 to 145.00 Rating: Buy
In 2012 The DOJ started and investigation in a stock I owned (QCOR) this investigation kept the share price depressed for over 2 years. QCOR eventually sold out to MNK. After 2 years and several FOIA requests we have never heard anything from the DOJ investigation. I expect the same is possible with TRN. GL